《大行報告》高盛下調申洲(02313.HK)目標價至140元 評級「買入」
高盛發表評級報告指,申洲(02313.HK)管理層預計今年上半年毛利率仍有挑戰、下半年則會有所改善,料今年銷量按年增15%;而按季度而言,今年首季產量已返回去年水平,料今年第二季按年增10%、今年第三季則按年增20%。
該行指,由於內地及越南疫情,以致短期內生產力、成本控制及擴張方面有較多不明朗,故管理層語調較該行預期的更為保守。該行預料,公司今年銷量按年增16%、人民幣平均售價按年增2%以及其毛利率27%。
該行將公司在2022年至23年每股盈利預測下調至13%及10%,並將其目標價由160元下調至140元,維持其評級為「買入」,以反映相信公司能從去年低基數恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.